Showing 1 posts of 1 posts found.
Novartis has signed an agreement with Cerulean Pharma, worth a potential $1.2 billion depending on milestones met, to co-develop nanoparticle-drug …
From lab breakthrough to NHS treatment: Getting innovative therapies to patients
Five Facts about NHS and primary care
Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
AI in pharma: From lab development to patient impact
Back to basics: X-ray inspection in pharmaceutical and medical device production